Piper Jaffray Revises EPS Estimates Of Alnylam Pharmaceuticals

According to Piper Jaffray, Alnylam Pharmaceuticals ALNY, EPS estimates have been revised. Piper Jaffray announced a decrease in FY11 EPS estimates from ($1.31) to ($1.33) and an increase in FY12 EPS estimates from ($1.86) to ($1.82). Rating of neutral and PT of $10 are both reiterated. Alnylam closed yesterday at $9.40.